How do you counsel patients eligible for the RSV vaccines? What do the results of the RENOIR and AReSVi trials tell us and how do they compare? How should we interpret vaccine trials in the first place? Tune in to the fourth episode of Beyond Journal Club, a new series brought to you by Core IM in collaboration with NEJM Group.

Sponsor: Pathway FREE evidence-based clinical decision support app. Guideline summaries, interactive algorithms, landmark trials & more

Show Notes & Transcript

Time Stamps:

(02:30) | Epidemiology of RSV

(03:46) | Development of RSV vaccine

(05:55) | Vaccine trial design

(12:22) | ARESVI and RENOIR Trials

(18:18) | Who should we recommend the RSV vaccine to?

(19:50) | What don’t we know?

Tags: IMCore, CoreIM, primary care, infectious disease, nurse practitioner, pharmacist, physician assistant

Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840

Our Sponsors:
* Check out Branch Basics and use my code branchbasics.com/COREIM for a great deal: https://branchbasics.com
* Check out Quince for high-quality clothes with affordable pricing and use code quince.com/coreim

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

#144 RSV & What Makes Vaccine Trials Different: Beyond Journal Club on the RENOIR and AReSVi Trials

Core IM | Internal Medicine Podcast

#144 RSV & What Makes Vaccine Trials Different: Beyond Journal Club on the RENOIR and AReSVi Trials